Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122–39.

Article  CAS  PubMed  Google Scholar 

Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, Gottlieb M. Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med. 2021;50:335–44.

Article  PubMed  Google Scholar 

Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17:3837–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–67.

Article  PubMed  Google Scholar 

Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiravand Y, Khodadadi F, Kashani S, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044–60.

Article  PubMed  PubMed Central  Google Scholar 

Boukouris AE, Theochari M, Stefanou D, Papalambros A, Felekouras E, Gogas H, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: a 2022 update. Crit Rev Oncol Hematol. 2022;173:103663.

Article  PubMed  Google Scholar 

Fuchs N, Zhang L, Calvo-Barreiro L, Kuncewicz K, Gabr M. Inhibitors of immune checkpoints: small molecule- and peptide-based approaches. J Pers Med. 2024;14:68.

Article  PubMed  PubMed Central  Google Scholar 

Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Q, Zhao X, Li S, Yang F, Wang H, Cui F, et al. CSF neurofilament light chain elevation predicts ALS severity and progression. Front Neurol. 2020;11:919.

Article  PubMed  PubMed Central  Google Scholar 

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.

Article  CAS  PubMed  Google Scholar 

Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295–316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775–90.

Article  PubMed  PubMed Central  Google Scholar 

Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wachsmann T, Wouters AK, Remst D, Hagedoorn RS, Meeuwsen MH, van Diest E, et al. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. OncoImmunology. 2022;11:2033528.

Article  PubMed  PubMed Central  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.

Article  CAS  PubMed  Google Scholar 

Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Liu G, Wang J, Zheng Z, Jia L, Rui W, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13:eabb5191.

Article  CAS  PubMed  Google Scholar 

Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28:345–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2:377–91.

Article  CAS  PubMed  Google Scholar 

Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19:5–18.

Article  PubMed  Google Scholar 

Barros L, Couto S, da Silva Santurio D, Paixão EA, Cardoso F, da Silva VJ, et al. Systematic review of available CAR-T cell trials around the world. Cancers. 2022;14:2667.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.

Article  CAS  PubMed  Google Scholar 

Drougkas K, Karampinos K, Karavolias I, Koumprentziotis IA, Ploumaki I, Triantafyllou E, et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? J Cancer Res Clin Oncol. 2023;149:2709–34.

Article  PubMed  Google Scholar 

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res J Am Assoc Cancer Res. 2015;21:4062–72.

Article  CAS